Saintes

Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.

This research focuses on women aged 18 to 65 with symptoms of acute cystitis without risk of complication. It aims to evaluate whether using a shared decision-making tool in pharmacies can help patients better understand the benefits and risks of taking antibiotics and adjust antibiotic use accordingly. The goal is to reduce unnecessary antibiotic prescriptions while still selecting patients who truly need treatment. Participants are divided into two groups. One group follows the standard French delegation protocol for acute cystitis management by pharmacists, which recommends systematic antibiotic therapy. The other group uses the same protocol supplemented with a shared decision-making tool to decide if antibiotics should be given based on patient preferences after being informed. This study compares antibiotic dispensing between these groups. After diagnosis and consent, patients receive care according to their group assignment. Researchers collect data on antibiotic prescriptions and patient demographics. Participants are followed up by phone 14 days later to assess antibiotic use, symptom impact using the Activity Impairment Assessment scale, satisfaction, decision confidence via the OConnor scale, and any medical visits. Antibiotic dispensing is tracked through national pharmacy records. The study runs from May 2026 to November 2026.

Researchers are conducting a large national study in France to follow children who were treated for solid tumors before the year 2000 and under the age of 19. The study aims to improve understanding of the long-term health and social effects caused by cancer and its treatments, such as chemotherapy and radiotherapy. It focuses on estimating risks of adverse outcomes and finding ways to provide better follow-up care for survivors. Participants medical records are reviewed to estimate the doses of radiation and chemotherapy received, and the study collects information from national registries and self-reported questionnaires about survivors health status, social conditions, and quality of life. The study also uses data from the French National Health Insurance system to track health expenses and care. The cohort will be followed for up to 20 years starting from 2011. During the study, researchers monitor all health events over time since the diagnosis of childhood cancer. Data collected include vital status, causes of death, social factors, and health care use. The study has already identified increased risks of secondary cancers and other diseases linked to treatments. Participants provide consent and allow access to health data, and the research aims to help identify survivors at higher risk to improve their long-term care.

Researchers are investigating the best noninvasive respiratory support method for patients in intensive care units ICUs who develop respiratory failure after planned removal of their breathing tube extubation. This condition affects about 20% of ICU patients, and many require reintubation, which is linked to high mortality rates. The study aims to compare whether alternating non-invasive ventilation NIV with high-flow nasal oxygen reduces death rates compared to high-flow nasal oxygen alone in these patients. The trial is a multicenter, randomized, controlled study where patients with post-extubation respiratory failure are assigned to one of two groups. One group receives continuous high-flow nasal oxygen treatment for 48 hours, while the other group receives NIV alternating with high-flow nasal oxygen during the same period. NIV involves pressure-support breathing with specific settings to help patients breathe, and the study ensures balance in patient groups based on carbon dioxide levels in the blood. Participants will be closely monitored with assessments including timing of death, reintubation events, days without ventilator use, length of ICU and hospital stay, and mortality at different time points up to 90 days. The main outcome measured is death rate 28 days after respiratory failure onset. The study includes clinical evaluations and blood gas tests to guide treatments and decisions. Participation duration includes the initial 48-hour treatment period and follow-up assessments extending to 90 days.